21
AUG
2020

Northwest Biotherapeutics Announces $5 Million Financing: Non-Dilutive Debt; No Amortization For 7 Months; Maturity of 21 Months

Posted By :
Comments : Off
BETHESDA, Md., August 19, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L for Glioblastoma brain cancer as described in the Company’s last report on July 24, 2020 has now been completed by the specialty analytic...
Read More
19
AUG
2020

NW Bio Announces Completion of Further Data Gathering For Phase III Trial

Posted By :
Comments : Off
BETHESDA, Md., August 19, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the remaining outstanding clinical trial data for the Company’s Phase 3 trial of DCVax®-L for Glioblastoma brain cancer as described in the Company’s last report on July 24, 2020 has now been completed by the specialty analytic...
Read More
11
AUG
2020

Northwest Biotherapeutics Announces $8 Million Financing: Financing On Favorable Terms; Further Broadening of Warrant Lock-Up

Posted By :
Comments : Off
BETHESDA, Md., August 11, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million.  The Company anticipates that this financing will help maintain the Company’s momentum, and will provide some prudent protection in the midst of the...
Read More
24
JUL
2020

Northwest Biotherapeutics Announces Completion of Phase 3 Trial Sites’ Databases

Posted By :
Comments : Off
BETHESDA, Md., July 24, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the data collection from all of the clinical trial sites for the Company’s Phase 3 trial of DCVax®-L for Glioblastoma brain cancer (the “Trial”) has been completed and all of the sites have signed off on the locking of their data. As noted...
Read More
02
JUN
2020

NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

Posted By :
Comments : Off
BETHESDA, Md., June 2, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer. The Company reported that the final data collection process has been progressing steadily despite ongoing difficulties due to coronavirus-related...
Read More